Roivant acquires a Glaxo Alzheimer’s compound
Roivant Sciences Ltd., via its wholly owned subsidiary Roivant Neurosciences Ltd., acquired GlaxoSmithKline PLC's Phase II SB742457 (GSK742457), a selective 5-HT6 antagonist for cognitive and other functional defects in neurological diseases. NOTES: Roivant Neurosciences is now called Axovant Sciences Ltd. and SB742457 was renamed RVT101.
- Specialty Pharmaceuticals
- Includes Contract
- Includes Royalty or Profit Split Information
- Product Purchase
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com